Details of the Drug

General Information of Drug (ID: DMGZQEF)

Drug Name
Mifepristone
Synonyms
Mifedren; HRA-052015; Mifepristone (Cushing's disease); ACTH modulator (Cushing's disease), HRA; Adrenocorticotropic hormone modulator (Cushing's disease), HRA Pharma; Mifepristone (Cushing's disease), HRA pharma
Indication
Disease Entry ICD 11 Status REF
Cushing disease 5A70 Approved [1], [2], [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 429.6
Topological Polar Surface Area (xlogp) 3.8
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 69% [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.5 mL/min/kg [6]
Elimination
The elimination of drug is 83% via feces and 9% via renal [7]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 hours [6]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 23.27704 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.45 L/kg [6]
Chemical Identifiers
Formula
C29H35NO2
IUPAC Name
(8S,11R,13S,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES
CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
InChI
InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1
InChIKey
VKHAHZOOUSRJNA-GCNJZUOMSA-N
Cross-matching ID
PubChem CID
55245
ChEBI ID
CHEBI:50692
CAS Number
84371-65-3
DrugBank ID
DB00834
TTD ID
D0Z4EI
VARIDT ID
DR00714
INTEDE ID
DR1091
ACDINA ID
D00432

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cushing disease
ICD Disease Classification 5A70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.82E-01 -6.00E-02 -2.69E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Mifepristone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Mifepristone and Pasireotide. Cushing syndrome [5A70] [36]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Mifepristone and Osilodrostat. Cushing syndrome [5A70] [36]
Coadministration of a Drug Treating the Disease Different from Mifepristone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Repaglinide DM5SXUV Moderate Decreased metabolism of Mifepristone caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [37]
Glibenclamide DM8JXPZ Moderate Decreased metabolism of Mifepristone caused by Glibenclamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [38]
Tolazamide DMIHRNA Moderate Decreased metabolism of Mifepristone caused by Tolazamide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [38]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Mifepristone caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [38]
Glipizide DMZA5PQ Moderate Decreased metabolism of Mifepristone caused by Glipizide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [38]
Ivosidenib DM8S6T7 Major Increased metabolism of Mifepristone caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [39]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Mifepristone and Midostaurin. Acute myeloid leukaemia [2A60] [36]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Mifepristone and Idarubicin. Acute myeloid leukaemia [2A60] [36]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Mifepristone and Arn-509. Acute myeloid leukaemia [2A60] [36]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Mifepristone and Gilteritinib. Acute myeloid leukaemia [2A60] [36]
Oliceridine DM6MDCF Major Decreased metabolism of Mifepristone caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [40]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Mifepristone and Rivastigmine. Alzheimer disease [8A20] [36]
Donepezil DMIYG7Z Minor Decreased metabolism of Mifepristone caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [41]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Mifepristone and Metronidazole. Amoebiasis [1A36] [37]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Mifepristone and Ivabradine. Angina pectoris [BA40] [42]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Mifepristone and Bepridil. Angina pectoris [BA40] [36]
Dronedarone DMA8FS5 Major Decreased metabolism of Mifepristone caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [43]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Mifepristone and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [36]
Methylphenobarbital DMDSWAG Moderate Increased metabolism of Mifepristone caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [38]
Cilostazol DMZMSCT Major Decreased metabolism of Mifepristone caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [44]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Mifepristone and Posaconazole. Aspergillosis [1F20] [38]
Terbutaline DMD4381 Major Increased risk of prolong QT interval by the combination of Mifepristone and Terbutaline. Asthma [CA23] [36]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Mifepristone and Pirbuterol. Asthma [CA23] [45]
Budesonide DMJIBAW Major Antagonize the effect of Mifepristone when combined with Budesonide. Asthma [CA23] [38]
Salbutamol DMN9CWF Major Increased risk of prolong QT interval by the combination of Mifepristone and Salbutamol. Asthma [CA23] [37]
Formoterol DMSOURV Moderate Increased risk of prolong QT interval by the combination of Mifepristone and Formoterol. Asthma [CA23] [45]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Mifepristone and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [36]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Mifepristone and Desipramine. Attention deficit hyperactivity disorder [6A05] [36]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Mifepristone and Ofloxacin. Bacterial infection [1A00-1C4Z] [36]
Tindamax DM3OWT4 Moderate Decreased metabolism of Mifepristone caused by Tindamax mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [37]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Mifepristone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [46]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Mifepristone and Clarithromycin. Bacterial infection [1A00-1C4Z] [38]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Mifepristone and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [36]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Mifepristone and Gemifloxacin. Bacterial infection [1A00-1C4Z] [36]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Mifepristone and Norfloxacin. Bacterial infection [1A00-1C4Z] [36]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Mifepristone and Levofloxacin. Bacterial infection [1A00-1C4Z] [36]
Troleandomycin DMUZNIG Major Decreased metabolism of Mifepristone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [38]
Lomefloxacin DMVRH9C Major Increased risk of prolong QT interval by the combination of Mifepristone and Lomefloxacin. Bacterial infection [1A00-1C4Z] [36]
Telithromycin DMZ4P3A Major Increased risk of prolong QT interval by the combination of Mifepristone and Telithromycin. Bacterial infection [1A00-1C4Z] [38]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Mifepristone and Retigabine. Behcet disease [4A62] [36]
Cariprazine DMJYDVK Major Decreased metabolism of Mifepristone caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [47]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Mifepristone caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [38]
Loperamide DMOJZQ9 Moderate Increased risk of prolong QT interval by the combination of Mifepristone and Loperamide. Bowel habit change [ME05] [48]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Mifepristone and Eribulin. Breast cancer [2C60-2C6Y] [36]
Talazoparib DM1KS78 Moderate Decreased clearance of Mifepristone due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [49]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Mifepristone caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Mifepristone and Lapatinib. Breast cancer [2C60-2C6Y] [36]
HKI-272 DM6QOVN Major Decreased metabolism of Mifepristone caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
LY2835219 DM93VBZ Moderate Decreased metabolism of Mifepristone caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Tucatinib DMBESUA Major Decreased metabolism of Mifepristone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [38]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Mifepristone caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Mifepristone caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Bosutinib DMTI8YE Major Decreased metabolism of Mifepristone caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Mifepristone caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [37]
Atorvastatin DMF28YC Moderate Decreased metabolism of Mifepristone caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [37]
Macitentan DMP79A1 Moderate Decreased metabolism of Mifepristone caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [51]
Corticotropin DMP9TWZ Major Decreased metabolism of Mifepristone caused by Corticotropin mediated inhibition of CYP450 enzyme. Chronic kidney disease [GB61] [38]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Mifepristone and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [36]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Mifepristone and Olodaterol. Chronic obstructive pulmonary disease [CA22] [45]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Mifepristone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [52]
Salmeterol DMIEU69 Moderate Increased risk of prolong QT interval by the combination of Mifepristone and Salmeterol. Chronic obstructive pulmonary disease [CA22] [45]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Mifepristone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [45]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Mifepristone and Arformoterol. Chronic obstructive pulmonary disease [CA22] [45]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Mifepristone caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [44]
Intedanib DMSTA36 Moderate Decreased metabolism of Mifepristone caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [53]
Isoproterenol DMK7MEY Major Increased risk of prolong QT interval by the combination of Mifepristone and Isoproterenol. Conduction disorder [BC63] [45]
Levobupivacaine DM783CH Moderate Decreased metabolism of Mifepristone caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [37]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Mifepristone and Halothane. Corneal disease [9A76-9A78] [36]
Ketamine DMT5HA4 Moderate Decreased metabolism of Mifepristone caused by Ketamine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [37]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Mifepristone and Probucol. Coronary atherosclerosis [BA80] [36]
Clofazimine DMEBOFW Major Increased risk of prolong QT interval by the combination of Mifepristone and Clofazimine. Crohn disease [DD70] [36]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Mifepristone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [37]
MK-8228 DMOB58Q Moderate Decreased metabolism of Mifepristone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [38]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Mifepristone and Sertraline. Depression [6A70-6A7Z] [36]
Vilazodone DM4LECQ Moderate Decreased metabolism of Mifepristone caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [37]
Nefazodone DM4ZS8M Major Decreased metabolism of Mifepristone caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [38]
Selegiline DM6034S Moderate Decreased metabolism of Mifepristone caused by Selegiline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [38]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Mifepristone and Escitalopram. Depression [6A70-6A7Z] [36]
OPC-34712 DMHG57U Major Decreased metabolism of Mifepristone caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [54]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Mifepristone and Clomipramine. Depression [6A70-6A7Z] [36]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Mifepristone and Doxepin. Depression [6A70-6A7Z] [36]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Mifepristone caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [55]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Mifepristone caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [44]
Oxybutynine DMJPBAX Moderate Decreased metabolism of Mifepristone caused by Oxybutynine mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [37]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Mifepristone and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [36]
Ospemifene DMC4GEI Moderate Decreased metabolism of Mifepristone caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [56]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Mifepristone and Deutetrabenazine. Dystonic disorder [8A02] [36]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Mifepristone and Ingrezza. Dystonic disorder [8A02] [36]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Mifepristone caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Cenobamate DMGOVHA Moderate Increased metabolism of Mifepristone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Tiagabine DMKSQG0 Moderate Decreased metabolism of Mifepristone caused by Tiagabine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Stiripentol DMMSDOY Moderate Decreased metabolism of Mifepristone caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Mifepristone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Clonazepam DMTO13J Moderate Decreased metabolism of Mifepristone caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Rufinamide DMWE60C Moderate Increased metabolism of Mifepristone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [44]
Phenobarbital DMXZOCG Moderate Increased metabolism of Mifepristone caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Cannabidiol DM0659E Minor Decreased metabolism of Mifepristone caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [44]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Mifepristone caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [37]
Tazemetostat DMWP1BH Moderate Decreased metabolism of Mifepristone caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [37]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Mifepristone and Solifenacin. Functional bladder disorder [GC50] [36]
Mirabegron DMS1GYT Minor Decreased metabolism of Mifepristone caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [57]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Mifepristone caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [37]
Itraconazole DMCR1MV Major Decreased metabolism of Mifepristone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [38]
Miconazole DMPMYE8 Moderate Decreased metabolism of Mifepristone caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [38]
Ketoconazole DMPZI3Q Major Decreased metabolism of Mifepristone caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [38]
Ripretinib DM958QB Major Decreased metabolism of Mifepristone caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [37]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Mifepristone and Sunitinib. Gastrointestinal stromal tumour [2B5B] [36]
Avapritinib DMK2GZX Major Decreased metabolism of Mifepristone caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [44]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Mifepristone caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [38]
Boceprevir DMBSHMF Major Decreased metabolism of Mifepristone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [38]
Telaprevir DMMRV29 Major Decreased metabolism of Mifepristone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [38]
Daclatasvir DMSFK9V Major Decreased metabolism of Mifepristone caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [44]
Isoniazid DM5JVS3 Moderate Decreased metabolism of Mifepristone caused by Isoniazid mediated inhibition of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [38]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Mifepristone due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [58]
MK-1439 DM215WE Minor Decreased metabolism of Mifepristone caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [59]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Mifepristone caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Mifepristone and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [36]
Cobicistat DM6L4H2 Major Decreased metabolism of Mifepristone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Dolutegravir DMCZGRE Minor Decreased metabolism of Mifepristone caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [60]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Mifepristone and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [38]
Etravirine DMGV8QU Moderate Decreased metabolism of Mifepristone caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [43]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Mifepristone and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [36]
Darunavir DMN3GCH Moderate Decreased metabolism of Mifepristone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Atazanavir DMSYRBX Major Decreased metabolism of Mifepristone caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Maraviroc DMTL94F Moderate Decreased metabolism of Mifepristone caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [37]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Mifepristone caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [37]
BMS-201038 DMQTAGO Major Decreased metabolism of Mifepristone caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [37]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Mifepristone caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [61]
Aliskiren DM1BV7W Moderate Decreased metabolism of Mifepristone caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [37]
Levamlodipine DM92S6N Moderate Decreased metabolism of Mifepristone caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [37]
Felodipine DMOSW35 Moderate Decreased metabolism of Mifepristone caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [37]
Irbesartan DMTP1DC Moderate Decreased metabolism of Mifepristone caused by Irbesartan mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [38]
Conivaptan DM1V329 Major Decreased metabolism of Mifepristone caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [37]
Tolvaptan DMIWFRL Major Decreased metabolism of Mifepristone caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [37]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Mifepristone caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [44]
Lesinurad DMUR64T Moderate Decreased metabolism of Mifepristone caused by Lesinurad mediated inhibition of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [38]
TP-434 DM5A31S Minor Decreased metabolism of Mifepristone caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [62]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Mifepristone caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [38]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Mifepristone caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
Amobarbital DM0GQ8N Moderate Increased metabolism of Mifepristone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [38]
Ramelteon DM7IW9J Moderate Decreased metabolism of Mifepristone caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [38]
Triazolam DMETYK5 Major Decreased metabolism of Mifepristone caused by Triazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [43]
Zaleplon DMGFWSM Moderate Decreased metabolism of Mifepristone caused by Zaleplon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Mifepristone caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [63]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Mifepristone caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
Estazolam DMZGXUM Moderate Decreased metabolism of Mifepristone caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [37]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Mifepristone and Polyethylene glycol. Irritable bowel syndrome [DD91] [44]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Mifepristone and Phenolphthalein. Irritable bowel syndrome [DD91] [36]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Mifepristone caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [64]
Naloxegol DML0B41 Major Decreased metabolism of Mifepristone caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [43]
Pemigatinib DM819JF Moderate Decreased metabolism of Mifepristone caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [44]
Crizotinib DM4F29C Major Decreased metabolism of Mifepristone caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [37]
Brigatinib DM7W94S Major Decreased metabolism of Mifepristone caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [65]
Ceritinib DMB920Z Major Decreased metabolism of Mifepristone caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [38]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Mifepristone caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [66]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Mifepristone and Osimertinib. Lung cancer [2C25] [36]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Mifepristone caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
Capmatinib DMYCXKL Major Decreased metabolism of Mifepristone caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [68]
Artemether DM48QOT Major Decreased metabolism of Mifepristone caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [37]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Mifepristone and Halofantrine. Malaria [1F40-1F45] [36]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Mifepristone and Hydroxychloroquine. Malaria [1F40-1F45] [36]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Mifepristone and Primaquine. Malaria [1F40-1F45] [36]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Mifepristone and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [36]
Idelalisib DM602WT Major Decreased metabolism of Mifepristone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [38]
GDC-0199 DMH0QKA Major Decreased clearance of Mifepristone due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [37]
IPI-145 DMWA24P Moderate Decreased metabolism of Mifepristone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [37]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Mifepristone and Arsenic trioxide. Mature B-cell lymphoma [2A85] [36]
Acalabrutinib DM7GCVW Major Decreased metabolism of Mifepristone caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [69]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Mifepristone caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [37]
Ponatinib DMYGJQO Moderate Decreased metabolism of Mifepristone caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [37]
Arry-162 DM1P6FR Moderate Decreased clearance of Mifepristone due to the transporter inhibition by Arry-162. Melanoma [2C30] [37]
Selumetinib DMC7W6R Moderate Decreased metabolism of Mifepristone caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [37]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Mifepristone and LGX818. Melanoma [2C30] [36]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Mifepristone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [38]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Mifepristone caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [44]
Danazol DML8KTN Moderate Decreased metabolism of Mifepristone caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [38]
Ubrogepant DM749I3 Major Decreased metabolism of Mifepristone caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [70]
Almogran DM7I64Z Moderate Decreased metabolism of Mifepristone caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [71]
Exjade DMHPRWG Moderate Decreased metabolism of Mifepristone caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [72]
Flibanserin DM70DTN Major Decreased metabolism of Mifepristone caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [73]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Mifepristone and Panobinostat. Multiple myeloma [2A83] [36]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Mifepristone and Thalidomide. Multiple myeloma [2A83] [37]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Mifepristone and Siponimod. Multiple sclerosis [8A40] [37]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Mifepristone and Fingolimod. Multiple sclerosis [8A40] [36]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Mifepristone and Romidepsin. Mycosis fungoides [2B01] [36]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Mifepristone and Nilotinib. Myeloproliferative neoplasm [2A20] [36]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Mifepristone caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [44]
Busulfan DMXYJ9C Moderate Decreased metabolism of Mifepristone caused by Busulfan mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [37]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Mifepristone and Promethazine. Nausea/vomiting [MD90] [36]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Mifepristone and Granisetron. Nausea/vomiting [MD90] [36]
Ondansetron DMOTQ1I Major Increased risk of prolong QT interval by the combination of Mifepristone and Ondansetron. Nausea/vomiting [MD90] [36]
Bupropion DM5PCS7 Moderate Decreased metabolism of Mifepristone caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [74]
Entrectinib DMMPTLH Major Decreased metabolism of Mifepristone caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [37]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Mifepristone caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [75]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Mifepristone and Lofexidine. Opioid use disorder [6C43] [36]
S-297995 DM26IH8 Moderate Decreased metabolism of Mifepristone caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [37]
Olaparib DM8QB1D Moderate Decreased metabolism of Mifepristone caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [37]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Mifepristone and Rucaparib. Ovarian cancer [2C73] [36]
Ibuprofen DM8VCBE Moderate Decreased metabolism of Mifepristone caused by Ibuprofen mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [38]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Mifepristone caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [76]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Mifepristone and Triclabendazole. Parasitic worm infestation [1F90] [36]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Mifepristone and Pimavanserin. Parkinsonism [8A00] [36]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Mifepristone caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [37]
Abametapir DM2RX0I Moderate Decreased metabolism of Mifepristone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [77]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Mifepristone and Famotidine. Peptic ulcer [DA61] [37]
Lanreotide acetate DMG6ZU4 Moderate Decreased metabolism of Mifepristone caused by Lanreotide acetate mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [38]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Mifepristone and Macimorelin. Pituitary gland disorder [5A60-5A61] [78]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Mifepristone and Lefamulin. Pneumonia [CA40] [36]
Ergonovine DM0VEC1 Major Decreased metabolism of Mifepristone caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [43]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Mifepristone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [79]
Ritodrine DM4V6RL Major Increased risk of prolong QT interval by the combination of Mifepristone and Ritodrine. Preterm labour/delivery [JB00] [45]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Mifepristone and Degarelix. Prostate cancer [2C82] [36]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Mifepristone and ABIRATERONE. Prostate cancer [2C82] [36]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Mifepristone and Enzalutamide. Prostate cancer [2C82] [36]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Mifepristone and Relugolix. Prostate cancer [2C82] [80]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Mifepristone and Bicalutamide. Prostate cancer [2C82] [36]
Silodosin DMJSBT6 Moderate Decreased metabolism of Mifepristone caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [37]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Mifepristone caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [37]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Mifepristone and Levomepromazine. Psychotic disorder [6A20-6A25] [36]
Selexipag DMAHSU0 Moderate Decreased metabolism of Mifepristone caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [81]
Ambrisentan DMD1QXW Minor Decreased metabolism of Mifepristone caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [82]
Axitinib DMGVH6N Major Decreased metabolism of Mifepristone caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [37]
Temsirolimus DMS104F Moderate Decreased metabolism of Mifepristone caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [37]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Mifepristone and Gatifloxacin. Respiratory infection [CA07-CA4Z] [36]
Upadacitinib DM32B5U Moderate Decreased metabolism of Mifepristone caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [37]
Tofacitinib DMBS370 Moderate Decreased metabolism of Mifepristone caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [37]
Dexamethasone DMMWZET Major Antagonize the effect of Mifepristone when combined with Dexamethasone. Rheumatoid arthritis [FA20] [38]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Mifepristone and Quetiapine. Schizophrenia [6A20] [36]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Mifepristone and Mesoridazine. Schizophrenia [6A20] [36]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Mifepristone caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [83]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Mifepristone and Iloperidone. Schizophrenia [6A20] [36]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Mifepristone and Paliperidone. Schizophrenia [6A20] [36]
Perphenazine DMA4MRX Major Increased risk of prolong QT interval by the combination of Mifepristone and Perphenazine. Schizophrenia [6A20] [36]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Mifepristone and Amisulpride. Schizophrenia [6A20] [36]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Mifepristone and Asenapine. Schizophrenia [6A20] [36]
Avanafil DM75CXN Major Decreased metabolism of Mifepristone caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [37]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Mifepristone and Vardenafil. Sexual dysfunction [HA00-HA01] [36]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Mifepristone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [38]
LDE225 DMM9F25 Moderate Decreased metabolism of Mifepristone caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [37]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Mifepristone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [44]
Larotrectinib DM26CQR Major Decreased metabolism of Mifepristone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
Methylprednisolone DM4BDON Major Antagonize the effect of Mifepristone when combined with Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [38]
Docetaxel DMDI269 Major Decreased clearance of Mifepristone due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [84]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Mifepristone caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Mifepristone and LEE011. Solid tumour/cancer [2A00-2F9Z] [36]
Prednisolone DMQ8FR2 Major Decreased metabolism of Mifepristone caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [38]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Mifepristone and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [36]
Taxol DMUOT9V Moderate Decreased metabolism of Mifepristone caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
Doxorubicin DMVP5YE Major Increased risk of prolong QT interval by the combination of Mifepristone and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [36]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Mifepristone and Pitolisant. Somnolence [MG42] [36]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Mifepristone and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [36]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Mifepristone caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [37]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Mifepristone due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [85]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Mifepristone and Lenvatinib. Thyroid cancer [2D10] [36]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Mifepristone and Papaverine. Tonus and reflex abnormality [MB47] [86]
Sirolimus DMGW1ID Major Decreased metabolism of Mifepristone caused by Sirolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [43]
Tacrolimus DMZ7XNQ Major Decreased metabolism of Mifepristone caused by Tacrolimus mediated inhibition of CYP450 enzyme. Transplant rejection [NE84] [43]
Tolbutamide DM02AWV Moderate Decreased metabolism of Mifepristone caused by Tolbutamide mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [38]
Saxagliptin DMGXENV Moderate Decreased metabolism of Mifepristone caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [37]
Elagolix DMB2C0E Moderate Decreased clearance of Mifepristone due to the transporter inhibition by Elagolix. Uterine fibroid [2E86] [87]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Mifepristone and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [37]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Mifepristone and Procainamide. Ventricular tachyarrhythmia [BC71] [36]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Mifepristone and Propafenone. Ventricular tachyarrhythmia [BC71] [36]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Mifepristone and Flecainide. Ventricular tachyarrhythmia [BC71] [36]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Mifepristone and Amiodarone. Ventricular tachyarrhythmia [BC71] [36]
⏷ Show the Full List of 265 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Mifepristone 300 mg tablet 300 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2805).
2 ClinicalTrials.gov (NCT02342002) Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial. U.S. National Institutes of Health.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
10 Evaluation of strategies for the assessment of drug-drug interactions involving cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750.
11 Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica. 2006 Apr;36(4):287-99.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
22 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
23 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
24 Drug Interactions Flockhart Table
25 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
26 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
27 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
28 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
29 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
30 Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
31 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
32 Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
33 Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
34 Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
35 PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
36 Canadian Pharmacists Association.
37 Cerner Multum, Inc. "Australian Product Information.".
38 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
39 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
40 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
41 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
42 Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
43 He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
44 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
45 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
46 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
47 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
48 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
49 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
50 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
51 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
52 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
53 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
54 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
55 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
56 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
57 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
58 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
59 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
60 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
61 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
62 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
63 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
64 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
65 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
66 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
67 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
68 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
69 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
70 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
71 Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
72 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
73 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
74 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
75 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
76 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
77 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
78 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
79 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
80 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
81 Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
82 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
83 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
84 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
85 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
86 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
87 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.